NEW YORK (GenomeWeb News) – CardioDx today said that it has joined a research effort launched by Duke University and the National Heart Lung and Blood Institute aimed at determining alternative diagnostic strategies for assessment of patients with symptoms that suggest coronary artery disease.
AssureRx Launches GeneSightRx ADHD
AssureRx Health this week launched a pharmacogenetic test, called GeneSightRx ADHD, for characterizing patients' response to a variety of attention deficit hyperactivity disorder drugs.
Researchers at the University of California, Davis have reeled in a $1 million grant from the W.M. Keck Foundation to study genetic variants that may be involved in some cases of coronary artery disease.
CardioDx will use the funding to complete additional studies that demonstrate the clinical utility of Corus CAD, continue to educate primary care physicians and cardiologists as to how the test can be used in the care of their patients, and reach out to payors to help them understand the circumstances under which they should pay for the test.
Quest, which plans to acquire Celera by the end of the month, could provide the financial backing to conduct prospective studies for the KIF6 test, or it could decide to scrap the KIF6 program altogether.